Opinion

Video

Benefits of Incorporating Fusion-Guided Biopsy into Practice

Author(s):

David I. Lee, MD, FACS,Firas F. Abdollah, MD

Firas F. Abdollah, MD, provides insights on how MRI- or fusion-guided technologies are used with transrectal and transperineal biopsy procedures and how they improve traditional biopsy procedures.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
      Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
      Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
      Post-RP incontinence: Low procedure rates examined
      Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
      Data link incontinence severity to post-radical prostatectomy care
      Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
      Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
      Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
      Expert discusses differentiating prostate cancer from age-related issues
      Howard Goldman, MD, discusses development of the Glean Urodynamics System
      Howard Goldman, MD, discusses development of the Glean Urodynamics System
      Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
      Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
      Ruben Olivares, MD, answers a question during a Zoom video interview
      Ruben Olivares, MD, discusses remote robot–assisted HIFU for prostate cancer
      Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
      Strategies to bridge gender disparities in AAS and citations in the oncology literature
      Stacy Loeb, MD, MSc, PhD (Hon), answers a question during a Zoom video interview
      Stacy Loeb, MD, MSc, PhD (Hon), discusses the nuances of prostate cancer screening
      Related Content
      Howard B. Goldman, MD, FACS
      June 23rd 2025

      The future of OAB treatment: Emerging nerve targets and AI may guide therapy

      Howard B. Goldman, MD
      Howard B. Goldman, MD, FACS, discusses innovations such as tibial nerve stimulation devices, pudendal nerve targeting, and alternative stimulation frequencies.
      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
      April 27th 2025

      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

      Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
      Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
      CHMP recommends EU approval of darolutamide plus ADT in mHSPC
      June 20th 2025

      CHMP recommends EU approval of darolutamide plus ADT in mHSPC

      Hannah Clarke
      The approval is supported by data from the pivotal phase 3 ARANOTE trial.
      Dr. Murphy on increasing diversity in cancer clinical trials
      February 29th 2024

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
      Phase 3 trial launches of ifinatamab deruxtecan vs chemotherapy in mCRPC
      June 18th 2025

      Phase 3 trial launches of ifinatamab deruxtecan vs chemotherapy in mCRPC

      Hannah Clarke
      The IDeate-Prostate01 trial plans to enroll approximately 1440 patients whose tumors progressed following prior treatment with an ARPI.
      Study to evaluate impact of ArteraAI on clinical decision-making for prostate cancer
      June 17th 2025

      Study to evaluate impact of ArteraAI on clinical decision-making for prostate cancer

      Hannah Clarke
      ArteraAI is a multimodal artificial intelligence biomarker test that can predict therapy benefit and prognosticate long-term outcomes in prostate cancer.
      © 2025 MJH Life Sciences

      All rights reserved.